Abstracts tagged "Bone density"

Abstract Number: 2369 • 2017 ACR/ARHP Annual Meeting
Relationship of Bone Mineral Density and Inflammatory Burden with Carotid Plaque Formation in Rheumatoid Arthritis: A 5-Year Prospective Study
Na Ri Kim, Jong Wan Kang, Jung Su Eun, Ji Hun Kim, Jin Young Kang, Gi Bum Bae, Sang Jin Lee, Eon Jeong Nam and Young Mo Kang, Division of Rheumatology, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea, Republic of (South)
Background/Purpose: Rheumatoid arthritis (RA) is a chronic and systemic inflammatory disease. The incidence of the cardiovascular (CV) disease is significantly increased in patients with RA…
Abstract Number: 2379 • 2017 ACR/ARHP Annual Meeting
Effect of DKK-1 and Osteoprotegerin on Bone Mass in Tightly Controlled Rheumatoid Arthritis
Javier Narváez¹, Irene Martin-Esteve², Andrea Zacarias³, Pedro Alia⁴, Estibaliz Loza⁵, Loreto Carmona⁵, Joan Miquel Nolla² and Carmen Gomez Vaquero⁶, ¹Rheumatology Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ²Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³Hospital Universitari de Bellvitge, Barcelona, Spain, ⁴Clinical Laboratory Service, Hospital Universitari de Bellvitge - IDIBELL, Barcelona, Spain, ⁵Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain, ⁶Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: To analyze the association between osteoprotegerin (OPG) and Dickkopf-related protein 1 (DKK-1) and the annual percent change (Δ%) in bone mineral density (BMD) in patients…
Abstract Number: 2L • 2016 ACR/ARHP Annual Meeting
Effect of Denosumab Compared with Risedronate in Glucocorticoid-Treated Individuals: Results from the 12-Month Primary Analysis of a Randomized, Double-Blind, Active-Controlled Study
K Saag¹, RB Wagman², P Geusens³, JD Adachi⁴, O Messina⁵, R Emkey⁶, R Chapurlat⁷, NS Daizadeh², N Pannacciulli² and WF Lems⁸, ¹University of Alabama at Birmingham, Birmingham, AL, USA, Birmingham, AL, ²Amgen Inc., Thousand Oaks, CA, ³Maastricht University, Maastricht, Netherlands, ⁴McMaster University, Hamilton, ON, Canada, ⁵Cosme Argerich Hospital, Buenos Aires, Argentina, ⁶Emkey Arthritis & Osteoporosis Clinic, Wyomissing, PA, ⁷Hôpital Edouard Herriot, Lyon, France, ⁸VU University Medical Centre, Amsterdam, Netherlands
Background/Purpose: Glucocorticoid (GC)-induced osteoporosis (GIOP) remains the most common secondary cause of osteoporosis. Despite approved therapies, many subjects do not receive GIOP prevention or treatment.…
Abstract Number: 2 • 2016 ACR/ARHP Annual Meeting
Rheumatoid Arthritis (RA)-Related Autoimmunity and Lumbar Bone Mineral Density in a Multi-Ethnic Community-Dwelling Population
Jan M. Hughes-Austin¹, Joachim H. Ix², Michael H. Criqui³, Ronit Katz⁴, Matthew Budoff⁵, Jon T. Giles⁶, Kiang Liu⁷ and Darcy S. Majka⁸, ¹Orthopaedic Surgery, University of California, San Diego, La Jolla, CA, ²University of California, San Diego, La Jolla, CA, ³Family Medicine and Public Health, University of California, San Diego, La Jolla, CA, ⁴University of Washington, Seattle, WA, ⁵Cardiology, Harbor-UCLA Medical Center, Torrance, CA, ⁶Rheumatology, Columbia University Medical Center, NY, NY, ⁷Department of Preventive Medicine, Northwestern University, Chicago, IL, ⁸Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Previous studies suggest that antibodies to citrullinated protein antigens (ACPA) contribute to decreased hand bone mineral density (BMD) in RA-free individuals. No evidence exists…
Abstract Number: 4 • 2016 ACR/ARHP Annual Meeting
Rheumatoid Arthritis (RA)-Related Joint Symptoms and Thoracic Bone Mineral Density in an RA-Free Community Dwelling Population
Jan M. Hughes-Austin¹, Joachim H. Ix², Samuel R. Ward³, M. Kristen Demoruelle⁴, V. Michael Holers⁵, Jill M. Norris⁶ and Kevin D. Deane⁷, ¹Orthopaedic Surgery, University of California, San Diego, La Jolla, CA, ²University of California, San Diego, La Jolla, CA, ³Radiology, Orthopaedic Surgery, and Bioengineering, University of California, San Diego, La Jolla, CA, ⁴1775 Aurora Ct, 1775 Aurora Ct, Aurora, CO, ⁵Rheumatology Division, University of Colorado School of Medicine, Aurora, CO, ⁶University of Colorado Denver, Aurora, CO, ⁷Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Osteoporosis, defined by Tscore < -2.5, is one of the main consequences of RA and it appears early in the disease. It is twice…
Abstract Number: 167 • 2016 ACR/ARHP Annual Meeting
Bone Mineral Density Loss in Clinically Suspect Arthralgia Is Associated with Subclinical Inflammation and Progression to Clinical Arthritis
L. Mangnus¹, H.W. van Steenbergen², M. Reijnierse³, J. Kälvesten^4,5,6 and A.H.M. van der Helm-van Mil², ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Radiology, Leiden University Medical Center, Leiden, Netherlands, ⁴Radiology, Faculty of Health Sciences, Linköping, Sweden, ⁵Center for Medical Image Science and Visualization, Linköping University, Linköping, Sweden, ⁶Sectra AB, Linköping, Sweden
Background/Purpose: Peripheral bone mineral density (BMD) can be decreased in early rheumatoid arthritis but it is unknown if BMD loss emerges already before arthritis is…
Abstract Number: 321 • 2016 ACR/ARHP Annual Meeting
Results of a Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Romosozumab in Men with Osteoporosis
EM Lewiecki¹, S Horlait², T Blicharski³, S Goemaere⁴, K Lippuner⁵, P Meisner⁶, PD Miller⁷, A Miyauchi⁸, J Maddox⁹, NS Daizadeh⁹ and A Grauer⁹, ¹New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ²Amgen Ltd., Uxbridge, United Kingdom, ³Medical University of Lublin, Lublin, Poland, ⁴Ghent University Hospital, Gent, Belgium, ⁵Bern University Hospital, Bern, Switzerland, ⁶UCB Pharma, Brussels, Belgium, ⁷Colorado Center for Bone Research, Lakewood, CO, ⁸Miyauchi Medical Center, Osaka, Japan, ⁹Amgen Inc., Thousand Oaks, CA
Background/Purpose: Treatment with romosozumab (Romo) has been shown to rapidly increase BMD in postmenopausal women with low BMD through a dual effect on bone, increasing…
Abstract Number: 343 • 2016 ACR/ARHP Annual Meeting
Correlation Between Metacarpal Cortical Bone Mineral Density Measured By Dual X-Ray Densitometry and Radiogrammetry on Early Arthritis Patients
Irene Llorente Cubas*¹, Leticia Merino-Meléndez², Ana M. Ortiz Garcia³, Saturnino González Ortega⁴, Eugenio Escolano⁵, Alberto Garcia-Vadillo⁶, Esther Vicente-Rabaneda², Rosario Garcia-Vicuña⁶, Isidoro Gonzalez-Alvaro³ and Santos Castañeda⁷, ¹Rheumatology, H.U La Princesa, Madrid, Spain, ²Rheumatology, H.U. La Princesa, Madrid, Spain, ³Rheumatology, Rheumatology Service, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ⁴X-ray diagnosis, X-ray diagnosis, Hospital de La Princesa, Madrid, Spain, ⁵Radiology Department, H.U La Princesa, Madrid, Spain, ⁶Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ⁷Rheumatology, Hospital de la Princesa, IIS-IP, Madrid, Spain
Background/Purpose: Low bone mass at metacarpal (MC) diaphysis measured by radiogrammetry (DXR) has been described as a poor prognostic factor in rheumatoid arthritis (RA). However,…
Abstract Number: 350 • 2016 ACR/ARHP Annual Meeting
Change in Bone Mineral Density with High-Dose Prednisone in Patients with Rheumatoid Arthritis
Linda Rasch¹, Lilian van Tuyl¹, Martijn Kremer², Irene E.M. Bultink², Maarten Boers^3,4 and Willem F. Lems^1,4, ¹Amsterdam Rheumatology and immunology Center | VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ²Rheumatology, Amsterdam Rheumatology and immunology Center | VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ³Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ⁴Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, Netherlands, Amsterdam, Netherlands
Background/Purpose: Recently, we showed that treatment with COBRA-light therapy including prednisone with initially 30 mg/day, was as effective as the original COBRA scheme, with initially…
Abstract Number: 359 • 2016 ACR/ARHP Annual Meeting
The Association of Scheuermann’s Disease with Osteoporotic Vertebral Fracture Risk
Marine Gaudé¹, R Chapurlat² and Pawel Szulc³, ¹Rheumatology, INSERM UMR 1033 and University of Lyon, Hôpital Edouard Herriot, Lyon, France, ²INSERM UMR 1033 and University of Lyon, Hôpital Edouard Herriot, Lyon, France, ³Epidemiology of Osteoporosis, INSERM UMR 1033, Lyon, France
Background/Purpose: Scheuermann’s disease is one of the most frequent illnesses of the spine in teenagers. Its evolution over time is poorly understood. Spinal deformities, by…
Abstract Number: 365 • 2016 ACR/ARHP Annual Meeting
Osteonecrosis of the Femoral Head Is Associated with Low Bone Mass.
muhammad soyfoo¹, Valérie Gangji², rodrigo moreno³, Joanne Rasschaert⁴ and Jean-Philippe Hauzeur⁵, ¹Rheumatology, Hôpital erasme, bruxelles, Belgium, ²Rheumatology, Hôpital Erasme,Université Libre de Bruxelles, Brussels, Belgium, ³nuclear medicine, erasme hospital, brussels, Belgium, ⁴Laboratory of Bone and Metabolic Biochemistry, Université Libre de Bruxelles, Brussels, Belgium, ⁵Rheumatology, Sart Tilman, Liège, Belgium
Background/Purpose: Osteonecrosis of the femoral head (ONFH) is characterized by epiphyseal necrosis that can lead to sub-chondral fracture, femoral head collapse and hip replacement. Osteoporosis…
Abstract Number: 513 • 2016 ACR/ARHP Annual Meeting
Low Serum 25-Hydroxyvitamin D Level Is Not Associated with Decreased Bone Mass or Bone Quality in Patients with Rheumatoid Arthritis
Kentaro Inui¹, Tatsuya Koike², Yuko Sugioka³, Tadashi Okano¹, Kenji Mamoto⁴, Masahiro Tada⁵ and Hiroaki Nakamura⁴, ¹Orthopaedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ²Center for Senile Degenerative Disorders, Osaka City University Medical School, Osaka, Japan, ³Center for Senile Degenerative Disorders (CSDD), Osaka City University Medical School, Osaka, Japan, ⁴Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ⁵Orthopedic Surgery, Osaka City General Hospital, Osaka, Japan
Background/Purpose: Vitamin D deficiency in patients with rheumatoid arthritis (RA) is commonly observed. Previous studies have investigated the relationship between vitamin D deficiency and RA…
Abstract Number: 1024 • 2016 ACR/ARHP Annual Meeting
Superior Gains in Bone Mineral Density and Estimated Strength at the Hip for Romosozumab Compared with Teriparatide in Women with Postmenopausal Osteoporosis Transitioning from Bisphosphonate Therapy: Results of a Phase 3, Open-Label Clinical Trial
B Langdahl¹, C Libanati², DB Crittenden³, MA Bolognese⁴, JP Brown⁵, NS Daizadeh³, K Engelke⁶, HK Genant⁷, S Goemaere⁸, Lars Hyldstrup⁹, E Jodar-Gimeno¹⁰, TM Keaveny¹¹, D Kendler¹², P Lakatos¹³, J Maddox³, J Malouf¹⁴, FE Massari¹⁵, JF Molina¹⁶, MR Ulla¹⁷ and A Grauer³, ¹Aarhus University Hospital, Aarhus, Denmark, ²UCB Pharma, Brussels, Belgium, ³Amgen Inc., Thousand Oaks, CA, ⁴Bethesda Health Research Center, Bethesda, MD, ⁵Laval University and CHU de Québec (CHUL) Research Centre, Quebec City, QC, Canada, ⁶BioClinica Inc., Hamburg, Germany, ⁷Department of Radiology, University of California San Francisco, San Francisco, CA, ⁸Ghent University Hospital, Gent, Belgium, ⁹Hvidovre University Hospital, Hvidovre, Denmark, ¹⁰Servicio de Endocrinología, Hospital Universitario Quirón, Madrid, Spain, ¹¹University of California at Berkeley, Berkeley, CA, ¹²University of British Columbia, Vancouver, BC, Canada, ¹³Department of Medicine, Semmelweis University, Budapest, Hungary, ¹⁴Universitat Autònoma de Barcelona, Barcelona, Spain, ¹⁵Instituto de Investigaciones Metabólicas, Buenos Aires, Argentina, ¹⁶Reumalab Centro Integral de Reumatologia, Medellin, Colombia, ¹⁷Instituto Latinoamericano de Investigaciones Médicas, Córdoba, Argentina
Background/Purpose: STRUCTURE was a phase 3, open-label study evaluating the effect of romosozumab or teriparatide for 12 months in women with postmenopausal osteoporosis transitioning from…
Abstract Number: 1531 • 2016 ACR/ARHP Annual Meeting
Decrease in Bone Mineral Density during Three Months of Early RA Measured By DXR Predicts Radiographic Joint Damage after One Year
Michael Ziegelasch¹, Kristina Forslind², Thomas Skogh³, Katrine Riklund⁴, Alf Kastbom⁵ and E. Berglin⁶, ¹Rheumatology/AIR, Linköping, Sweden, ²Department of Medicine, Helsingborgs Lasarett, Section of Rheumatology, Helsingborg, Sweden, ³IKE/Rheumatology, Linköping University, Linköping, Sweden, ⁴Departments of Diagnostic radiology, Umeå university, Umeå, Sweden, ⁵Department of Clinical and Experimental Medicine, Rheumatology/AIR, Linköping, Sweden, ⁶Department of Publiic Health and Clinical Medicin/Rheumatology, Umeå university, Umea, Sweden
Background/Purpose: Digital X-ray radiogrammetry (DXR) is a method to calculate peripheral bone mineral density (BMD) which calculates BMD of the hands (DXR-BMD). The aim…
Abstract Number: 2541 • 2016 ACR/ARHP Annual Meeting
Glucocorticoid Use and Low Thoracic Bone Mineral Density Are Predictors for Clinical Fractures in Patients with Rheumatoid Arthritis: Five-Year Findings of the Tomorrow Study
Kenji Mamoto¹, Kentaro Inui², Tadashi Okano¹, Yuko Sugioka³, Masahiro Tada⁴, Tatsuya Koike⁵ and Hiroaki Nakamura⁶, ¹Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ²Rheumatology & Orthopaedics, Higashisumiyoshi Morimoto Hospital, Osaka, Japan, ³o, Osaka, Japan, ⁴Orthopedic Surgery, Osaka City General Hospital, Osaka, Japan, ⁵Center for Senile Degenerative Disorders (CSDD), Osaka City University Graduate School of Medicine, Osaka, Japan, ⁶Orthopaedic Surgery, Osaka City University Medical School, Osaka, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) who have muscle weakness and stiff or painful joints might be at increased risk of falls and fractures. The…

« Previous Page
1
…
7
8
9
10
11
…
14
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].